FindTrial
Sign In

To compare the effect of pioglitazone vs vildagliptin in type 2 diabetes mellitus patients not responding to combination of metformin and sulfonylureas.

Efficacy of add on therapy of Vildagliptin versus Pioglitazone in inadequately controlled Type 2 Diabetes Mellitus patients on dual therapy of Metformin plus Sulfonylurea

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/04/003582
Enrollment
50
Registered
2013-04-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Type 2 Diabetes Mellitus patients uncontrolled with metformin and sulfonylureas

Interventions

Intervention1: Pioglitazone 30 mg/day : Patients were given Pioglitazone 30 mg/day plus the drugs (metformin and sulfonlyureas) which they were taking already. The patients were followed for 12 weeks

Sponsors

investigator initiated trial
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Type 2 DM, taking a combination of metformin + sulfonylurea (glibenclamide or glipizide or gliclazide or glimepride) for at least last 3 months with HbA1c >7% 25 kg/m2, FBS >126 mg/dl

Exclusion criteria

Exclusion criteria: Pregnant and lactating females, patients on insulin therapy, history of type 1 DM, evidence of diabetic complications (nephropathy, neuropathy and retinopathy), patients with clinical signs and symptoms of acute myocardial infarction, liver failure, chronic heart failure and renal failure

Design outcomes

Primary

MeasureTime frame
HbA1c levelsTimepoint: 0 week and 12 weeks—

Secondary

MeasureTime frame
Fasting plasma glucose levels (mg/dl)Timepoint: Baseline (0 week) and at week 12—

Countries

India

Contacts

Public ContactKirandeep Kaur

DMCH

kiransondhi@gmail.com9815277755

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 8, 2026